|
G |
Casp2 |
caspase 2 |
increases expression decreases expression multiple interactions |
ISO |
tetraiodothyroacetic acid results in increased expression of CASP2 mRNA tetraiodothyroacetic acid results in decreased expression of CASP2 mRNA heteronemin inhibits the reaction [tetraiodothyroacetic acid results in increased expression of CASP2 mRNA]; heteronemin promotes the reaction [tetraiodothyroacetic acid results in decreased expression of CASP2 mRNA]; tetraiodothyroacetic acid inhibits the reaction [heteronemin results in decreased expression of CASP2 mRNA] |
CTD |
PMID:35151786 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
tetraiodothyroacetic acid results in increased expression of CASP3 protein modified form heteronemin promotes the reaction [tetraiodothyroacetic acid results in increased expression of CASP3 protein modified form]; tetraiodothyroacetic acid promotes the reaction [heteronemin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:35151786 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression |
ISO |
[tetraiodothyroacetic acid affects the susceptibility to heteronemin] which results in increased expression of CASP8 protein modified form; heteronemin promotes the reaction [tetraiodothyroacetic acid results in increased expression of CASP8 protein modified form] tetraiodothyroacetic acid results in increased expression of CASP8 protein; tetraiodothyroacetic acid results in increased expression of CASP8 protein modified form |
CTD |
PMID:35151786 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions decreases expression |
ISO |
tetraiodothyroacetic acid inhibits the reaction [heteronemin results in increased expression of CASP9 protein modified form] tetraiodothyroacetic acid results in decreased expression of CASP9 protein |
CTD |
PMID:35151786 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
tetraiodothyroacetic acid results in decreased expression of CCND1 mRNA [heteronemin affects the susceptibility to tetraiodothyroacetic acid] which results in decreased expression of CCND1 protein; [tetraiodothyroacetic acid affects the susceptibility to heteronemin] which results in decreased expression of CCND1 mRNA; [tetraiodothyroacetic acid affects the susceptibility to heteronemin] which results in increased expression of CCND1 protein; heteronemin inhibits the reaction [tetraiodothyroacetic acid results in decreased expression of CCND1 mRNA]; tetraiodothyroacetic acid promotes the reaction [heteronemin results in decreased expression of CCND1 protein] |
CTD |
PMID:35151786 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions increases expression |
ISO |
tetraiodothyroacetic acid results in decreased expression of CDKN1A mRNA heteronemin inhibits the reaction [tetraiodothyroacetic acid results in decreased expression of CDKN1A mRNA]; heteronemin inhibits the reaction [tetraiodothyroacetic acid results in increased expression of CDKN1A mRNA]; tetraiodothyroacetic acid inhibits the reaction [heteronemin affects the expression of CDKN1A mRNA]; tetraiodothyroacetic acid inhibits the reaction [heteronemin results in decreased expression of CDKN1A mRNA] |
CTD |
PMID:35151786 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression multiple interactions |
ISO |
tetraiodothyroacetic acid results in increased expression of CYCS protein tetraiodothyroacetic acid promotes the reaction [heteronemin results in increased expression of CYCS protein] |
CTD |
PMID:35151786 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Kdr |
kinase insert domain receptor |
decreases phosphorylation |
ISO |
tetraiodothyroacetic acid results in decreased phosphorylation of KDR protein |
CTD |
PMID:35151786 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases expression |
ISO EXP |
[heteronemin affects the susceptibility to tetraiodothyroacetic acid] which results in decreased expression of MAPK1 protein modified form; heteronemin promotes the reaction [tetraiodothyroacetic acid results in decreased expression of MAPK1 protein modified form]; tetraiodothyroacetic acid promotes the reaction [heteronemin results in decreased expression of MAPK1 protein modified form] tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK1 protein] |
CTD |
PMID:17984113 PMID:35151786 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases expression |
ISO EXP |
[heteronemin affects the susceptibility to tetraiodothyroacetic acid] which results in decreased expression of MAPK3 protein modified form; heteronemin promotes the reaction [tetraiodothyroacetic acid results in decreased expression of MAPK3 protein modified form]; tetraiodothyroacetic acid promotes the reaction [heteronemin results in decreased expression of MAPK3 protein modified form] tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK3 protein] |
CTD |
PMID:17984113 PMID:35151786 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
tetraiodothyroacetic acid results in decreased expression of MMP9 mRNA heteronemin inhibits the reaction [tetraiodothyroacetic acid results in decreased expression of MMP9 mRNA]; tetraiodothyroacetic acid inhibits the reaction [heteronemin results in increased expression of MMP9 mRNA] |
CTD |
PMID:35151786 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
tetraiodothyroacetic acid promotes the reaction [THRA protein binds to NCOA2 protein]; tetraiodothyroacetic acid promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]] |
CTD |
PMID:22227104 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]] |
CTD |
PMID:22227104 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression decreases expression |
ISO |
[tetraiodothyroacetic acid affects the susceptibility to heteronemin] which results in increased expression of PCNA protein; heteronemin inhibits the reaction [tetraiodothyroacetic acid results in increased expression of PCNA protein]; heteronemin promotes the reaction [tetraiodothyroacetic acid results in decreased expression of PCNA mRNA]; tetraiodothyroacetic acid promotes the reaction [heteronemin results in decreased expression of PCNA mRNA] |
CTD |
PMID:35151786 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
tetraiodothyroacetic acid binds to RXRA protein |
CTD |
PMID:31566444 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases expression |
ISO |
[heteronemin co-treated with tetraiodothyroacetic acid] results in decreased expression of STAT3 protein tetraiodothyroacetic acid results in decreased expression of STAT3 protein modified form |
CTD |
PMID:35151786 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of THRA protein; tetraiodothyroacetic acid promotes the reaction [THRA protein binds to NCOA2 protein] |
CTD |
PMID:31566444 PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions affects binding increases activity |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of THRB protein; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; tetraiodothyroacetic acid promotes the reaction [THRB protein binds to NCOA2 protein] tetraiodothyroacetic acid binds to THRB protein tetraiodothyroacetic acid results in increased activity of THRB protein |
CTD |
PMID:22227104 PMID:31077750 PMID:31566444 PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression |
EXP ISO |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of TP53 protein modified form] [heteronemin affects the susceptibility to tetraiodothyroacetic acid] which results in decreased expression of TP53 mRNA; heteronemin promotes the reaction [tetraiodothyroacetic acid results in decreased expression of TP53 mRNA]; tetraiodothyroacetic acid promotes the reaction [heteronemin results in decreased expression of TP53 mRNA] |
CTD |
PMID:17984113 PMID:35151786 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Aadat |
aminoadipate aminotransferase |
decreases activity |
EXP |
Triiodothyronine results in decreased activity of AADAT protein |
CTD |
PMID:32663543 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ABCA1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in decreased activity of ABCB11 protein Triiodothyronine results in increased expression of ABCB11 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCB11 mRNA |
CTD |
PMID:28437613 PMID:34902352 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Triiodothyronine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ABCC5 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcf3 |
ATP binding cassette subfamily F member 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ABCF3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr11:80,340,476...80,352,211
Ensembl chr11:80,339,977...80,352,211
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of ABCG5 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG5 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of ABCG8 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG8 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases expression increases activity |
EXP ISO |
Triiodothyronine inhibits the reaction [Streptozocin results in decreased activity of ACACA protein]; Triiodothyronine inhibits the reaction [Streptozocin results in decreased expression of ACACA mRNA] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Triiodothyronine results in increased expression of ACACA mRNA Triiodothyronine results in increased activity of ACACA protein |
CTD |
PMID:1973097 PMID:33476690 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acbd4 |
acyl-CoA binding domain containing 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ACBD4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:88,048,058...88,062,612
Ensembl chr10:88,048,108...88,058,500
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of and results in increased activity of ACE protein |
CTD |
PMID:1659346 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression decreases expression |
EXP |
Triiodothyronine results in increased expression of ACOT1 mRNA Triiodothyronine results in decreased expression of ACOT1 mRNA |
CTD |
PMID:15953391 PMID:28299817 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions increases expression |
EXP |
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ACOX1 mRNA Triiodothyronine results in increased expression of ACOX1 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ACSL1 mRNA |
CTD |
PMID:30209975 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ACSL5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ACVRL1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adam11 |
ADAM metallopeptidase domain 11 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADAM11 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADAM12 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ADAM15 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ADAM19 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Add2 |
adducin 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADD2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:118,444,594...118,538,505
Ensembl chr 4:118,497,416...118,538,505
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] |
CTD |
PMID:33476690 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ADRB1 mRNA; Triiodothyronine results in increased expression of ADRB1 protein |
CTD |
PMID:10217540 PMID:11090638 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases expression |
ISO |
bicalutamide inhibits the reaction [Triiodothyronine results in increased expression of ADRB2 protein] Triiodothyronine results in increased expression of ADRB2 mRNA; Triiodothyronine results in increased expression of ADRB2 protein |
CTD |
PMID:18454446 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions decreases expression increases expression |
EXP |
Amiodarone inhibits the reaction [Triiodothyronine results in decreased expression of ADRB3 protein] Triiodothyronine results in decreased expression of ADRB3 mRNA; Triiodothyronine results in decreased expression of ADRB3 protein Triiodothyronine results in increased expression of ADRB3 protein |
CTD |
PMID:8836703 PMID:10217540 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA] |
CTD |
PMID:28478156 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKAP12 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akirin2 |
akirin 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKIRIN2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 5:49,108,231...49,122,566
Ensembl chr 5:49,108,220...49,122,568
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C2 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16021636 PMID:18096819 PMID:36868496 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Triiodothyronine binds to ALB protein |
CTD |
PMID:21517007 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions |
EXP |
Triiodothyronine affects the reaction [Propylthiouracil affects the expression of AMH mRNA] |
CTD |
PMID:7819453 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Angptl8 |
angiopoietin-like 8 |
multiple interactions |
ISO |
[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24262987 |
|
NCBI chr 8:20,376,462...20,378,488
Ensembl chr 8:20,376,462...20,378,490
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of APOA1 protein |
CTD |
PMID:6816881 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa4 |
apolipoprotein A4 |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein] |
CTD |
PMID:6816881 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein] |
CTD |
PMID:6816881 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
decreases expression multiple interactions |
ISO EXP |
Triiodothyronine results in decreased expression of APP mRNA; Triiodothyronine results in decreased expression of APP protein Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of APP protein modified form] Tretinoin promotes the reaction [Triiodothyronine results in decreased secretion of APP protein] |
CTD |
PMID:17199430 PMID:36868496 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AQP1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp8 |
aquaporin 8 |
increases expression |
EXP |
Triiodothyronine results in increased expression of AQP8 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgef25 |
Rho guanine nucleotide exchange factor 25 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ARHGEF25 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:63,005,938...63,013,325
Ensembl chr 7:63,005,940...63,013,719
|
|
G |
Arl4d |
ADP-ribosylation factor like GTPase 4D |
increases expression |
ISO |
Triiodothyronine results in increased expression of ARL4D mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ARRDC3 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Aspg |
asparaginase |
increases expression |
EXP |
Triiodothyronine results in increased expression of ASPG mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268
|
|
G |
Aspm |
assembly factor for spindle microtubules |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ASPM mRNA |
CTD |
PMID:23397585 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Atg5 |
autophagy related 5 |
increases expression affects response to substance |
ISO |
Triiodothyronine results in increased expression of ATG5 mRNA; Triiodothyronine results in increased expression of ATG5 protein ATG5 protein affects the susceptibility to Triiodothyronine |
CTD |
PMID:30209975 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ATG7 mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ATP1B2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions increases expression |
EXP |
THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:11577024 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of BACE1 protein] |
CTD |
PMID:36868496 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression |
ISO EXP |
Triiodothyronine results in decreased expression of BAD protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO EXP |
Triiodothyronine results in decreased expression of BAX protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Triiodothyronine promotes the reaction [tamibarotene results in decreased expression of BCL2 mRNA] Triiodothyronine results in increased expression of BCL2 protein |
CTD |
PMID:11201846 PMID:16021636 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [tamibarotene results in increased expression of BCL2A1A mRNA] |
CTD |
PMID:11201846 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of BCL2L1 protein |
CTD |
PMID:16021636 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
EXP |
Triiodothyronine results in increased expression of BCL3 mRNA |
CTD |
PMID:22015988 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BMP2 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bmp8a |
bone morphogenetic protein 8a |
multiple interactions |
ISO |
[mono-(2-ethylhexyl)phthalate co-treated with Triiodothyronine] results in increased expression of BMP8B mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 5:135,589,839...135,617,785
Ensembl chr 5:135,591,716...135,617,785
|
|
G |
Capns1 |
calpain, small subunit 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CAPNS1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
EXP ISO |
Triiodothyronine results in decreased expression of CASP3 protein THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA] |
CTD |
PMID:16021636 PMID:32223187 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein; gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Triiodothyronine results in decreased activity of CAT protein] |
CTD |
PMID:12516873 PMID:23391542 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc71 |
coiled-coil domain containing 71 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of CCDC71 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 8:109,146,650...109,161,749
Ensembl chr 8:109,146,359...109,165,216
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CCL5 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccna2 |
cyclin A2 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of CCNA2 protein |
CTD |
PMID:16021636 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of CCND1 protein Triiodothyronine results in increased expression of CCND1 mRNA; Triiodothyronine results in increased expression of CCND1 protein THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of CCND1 mRNA] |
CTD |
PMID:16021636 PMID:20638743 PMID:28315333 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of CCNE1 protein Triiodothyronine results in increased expression of CCNE1 mRNA; Triiodothyronine results in increased expression of CCNE1 protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdc45 |
cell division cycle 45 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CDC45 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDKN1A mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CDKN1A mRNA]; Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein] |
CTD |
PMID:14761676 PMID:22383522 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression multiple interactions |
EXP ISO |
Triiodothyronine results in decreased expression of CDKN1B mRNA; Triiodothyronine results in decreased expression of CDKN1B protein THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein] |
CTD |
PMID:16021636 PMID:20638743 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cep15 |
centrosomal protein 15 |
increases expression |
EXP |
Triiodothyronine results in increased expression of CEP15 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression |
EXP |
Triiodothyronine results in increased expression of CES2C mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions decreases expression |
EXP |
Phenelzine inhibits the reaction [Triiodothyronine results in decreased expression of CGA mRNA]; Triiodothyronine inhibits the reaction [Phenelzine results in increased expression of CGA mRNA] |
CTD |
PMID:20148560 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases phosphorylation |
ISO |
Triiodothyronine analog results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:22383522 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of CHST1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883
|
|
G |
Clu |
clusterin |
increases expression |
EXP |
Triiodothyronine results in increased expression of CLU mRNA |
CTD |
PMID:7531505 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions increases expression |
EXP |
ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA]; troglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16023420 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
EXP |
Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] Triiodothyronine results in increased expression of COL1A1 mRNA |
CTD |
PMID:18031379 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
increases expression |
ISO |
Triiodothyronine results in increased expression of COL6A3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Coq10b |
coenzyme Q10B |
increases expression |
EXP |
Triiodothyronine results in increased expression of COQ10B mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
multiple interactions increases expression |
ISO |
Chloroquine promotes the reaction [Triiodothyronine results in increased expression of COX4I1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of CPT1A mRNA Triiodothyronine results in increased expression of CPT1A mRNA; Triiodothyronine results in increased expression of CPT1A protein resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA] [BMS201038 co-treated with Triiodothyronine] results in increased expression of CPT1A mRNA; Resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA] |
CTD |
PMID:23209300 PMID:25048947 PMID:34902352 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression |
ISO |
Triiodothyronine results in increased expression of CPT1B mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cracr2b |
calcium release activated channel regulator 2B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of CRACR2B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:196,558,407...196,563,961
Ensembl chr 1:196,558,588...196,563,771
|
|
G |
Crat |
carnitine O-acetyltransferase |
increases expression |
EXP |
Triiodothyronine results in increased expression of CRAT mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
increases expression |
EXP |
Triiodothyronine results in increased expression of CSAD mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]] |
CTD |
PMID:9664232 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Ctse |
cathepsin E |
increases expression |
EXP |
Triiodothyronine results in increased expression of CTSE mRNA |
CTD |
PMID:15953391 |
|
NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA] |
CTD |
PMID:32223187 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] |
CTD |
PMID:21726595 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] |
CTD |
PMID:21726595 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:34571837 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Triiodothyronine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:28478156 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP1A2 mRNA Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 protein] |
CTD |
PMID:28478156 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP24A1 mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity increases expression |
EXP |
Triiodothyronine results in increased activity of CYP2E1 protein Triiodothyronine results in increased expression of CYP2E1 protein |
CTD |
PMID:14631868 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP3A4 mRNA SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:10393316 PMID:29357290 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression |
ISO |
Triiodothyronine results in increased expression of DBP mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of DECR2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
affects abundance multiple interactions increases expression affects metabolic processing increases chemical synthesis |
ISO EXP |
DIO1 gene SNP affects the abundance of Triiodothyronine 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA] [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine] DIO1 protein affects the metabolism of Triiodothyronine Arsenic affects the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]; Pentachlorophenol inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA] DIO1 protein results in increased chemical synthesis of Triiodothyronine |
CTD |
PMID:15254343 PMID:16131326 PMID:17105838 PMID:18288313 PMID:21565810 PMID:23397585 PMID:24001430 PMID:25646720 PMID:27420076 PMID:28167136 PMID:29357290 More...
|
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions decreases expression increases expression increases chemical synthesis |
ISO EXP |
2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; kaempferol promotes the reaction [DIO2 protein results in increased activity of and results in increased abundance of Triiodothyronine] Triiodothyronine results in decreased expression of DIO2 mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA Triiodothyronine results in increased expression of DIO2 mRNA DIO2 protein results in increased chemical synthesis of Triiodothyronine |
CTD |
PMID:17327447 PMID:17615150 PMID:23397585 PMID:25646720 PMID:26004626 PMID:34571837 More...
|
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of DIO3 mRNA Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of DIO3 mRNA] [Aurothioglucose results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [xanthohumol results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine |
CTD |
PMID:23397585 PMID:25962824 PMID:34571837 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlx2 |
distal-less homeobox 2 |
multiple interactions |
ISO |
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of DLX2 mRNA |
CTD |
PMID:34289950 |
|
NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dmbt1 |
deleted in malignant brain tumors 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DMBT1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478
|
|
G |
Dmpk |
DM1 protein kinase |
increases expression |
EXP |
Triiodothyronine results in increased expression of DMPK mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593
|
|
G |
Dmtn |
dematin actin binding protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of DMTN mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:45,677,974...45,702,261
Ensembl chr15:45,677,977...45,705,601
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
multiple interactions decreases expression |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DUSP2 mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of DUSP2 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dync1li2 |
dynein, cytoplasmic 1 light intermediate chain 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of DYNC1LI2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr19:531,783...554,670
Ensembl chr19:531,812...554,670
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ECH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Efcab3 |
EF-hand calcium binding domain 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of EFCAB3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:89,583,526...90,077,260
Ensembl chr10:89,644,522...90,077,259
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP ISO |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA] Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11742803 PMID:16150908 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation |
ISO |
Triiodothyronine results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:30209975 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eml2 |
EMAP like 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of EML2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:78,827,595...78,859,342
Ensembl chr 1:78,828,080...78,859,341
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ENO1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of EPAS1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Triiodothyronine results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression decreases expression |
ISO |
Tamoxifen inhibits the reaction [Triiodothyronine results in decreased expression of ESR1 mRNA]; Triiodothyronine binds to and results in increased activity of ESR1 protein [Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of ESR1 mRNA; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of ESR1 mRNA] |
CTD |
PMID:19942988 PMID:33049310 PMID:34571837 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP ISO |
[Arsenic co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of ESR2 mRNA; [bisphenol A co-treated with Zearalenone co-treated with Arsenic co-treated with enzacamene co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in increased expression of ESR2 mRNA; [enzacamene co-treated with Estradiol co-treated with Triiodothyronine] affects the expression of ESR2 mRNA; [Estradiol co-treated with Triiodothyronine] inhibits the reaction [bisphenol A results in decreased expression of ESR2 mRNA]; [Estradiol co-treated with Triiodothyronine] promotes the reaction [Zearalenone results in decreased expression of ESR2 mRNA]; [Zearalenone co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [Zearalenone results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in decreased expression of ESR2 mRNA Triiodothyronine binds to and results in increased activity of ESR2 protein |
CTD |
PMID:27338438 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ethe1 |
ETHE1, persulfide dioxygenase |
increases expression |
EXP |
Triiodothyronine results in increased expression of ETHE1 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:80,184,037...80,199,092
Ensembl chr 1:80,183,894...80,199,052
|
|
G |
Eva1c |
eva-1 homolog C |
increases expression |
ISO |
Triiodothyronine results in increased expression of EVA1C mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:30,089,510...30,163,596
Ensembl chr11:30,089,365...30,163,596
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of FABP4 mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA] |
CTD |
PMID:15953391 PMID:33476690 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FABP5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FADS2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam171b |
family with sequence similarity 171, member B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FAM171B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127
|
|
G |
Fam83h |
family with sequence similarity 83, member H |
increases expression |
ISO |
Triiodothyronine results in increased expression of FAM83H mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:107,716,431...107,724,619
Ensembl chr 7:107,716,431...107,728,672
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of FASN mRNA [pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of FASN mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA] |
CTD |
PMID:15953391 PMID:33476690 PMID:34289950 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FDFT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of FDPS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16150908 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO EXP |
Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:11742803 PMID:12805413 PMID:16150908 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FGF7 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16150908 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of FGFR1 mRNA Triiodothyronine results in increased expression of FGFR1 mRNA; Triiodothyronine results in increased expression of FGFR1 protein Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Dactinomycin inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]] |
CTD |
PMID:12805413 PMID:16150908 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FGFR2 mRNA |
CTD |
PMID:16150908 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FGFR3 mRNA |
CTD |
PMID:16150908 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fkbp10 |
FKBP prolyl isomerase 10 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FKBP10 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330
|
|
G |
Flrt1 |
fibronectin leucine rich transmembrane protein 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FLRT1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:204,275,785...204,292,844
Ensembl chr 1:204,275,367...204,353,750
|
|
G |
Foxo6 |
forkhead box O6 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FOXO6 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:133,856,087...133,876,387
Ensembl chr 5:133,856,072...133,876,573
|
|
G |
Fpgs |
folylpolyglutamate synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of FPGS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA] |
CTD |
PMID:7531505 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FXYD2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GAP43 mRNA; Triiodothyronine results in increased expression of GAP43 protein |
CTD |
PMID:15708448 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gba1 |
glucosylceramidase beta 1 |
increases activity |
EXP |
Triiodothyronine results in increased activity of GBA1 protein |
CTD |
PMID:9101438 |
|
NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GCH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions increases expression |
EXP ISO |
Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Amiodarone inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; bisphenol A promotes the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Dexamethasone promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Edetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]; Triiodothyronine results in increased expression of and results in increased secretion of GH protein; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]] Triiodothyronine results in increased expression of GH mRNA; Triiodothyronine results in increased expression of GH1 mRNA; Triiodothyronine results in increased expression of GH1 protein |
CTD |
PMID:2211641 PMID:2910914 PMID:10720163 PMID:15240998 PMID:17090972 PMID:17928132 PMID:22201216 PMID:24001430 PMID:27420076 More...
|
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
EXP |
Triiodothyronine promotes the reaction [Dexamethasone results in increased expression of GHRH mRNA] |
CTD |
PMID:17090972 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of GJA1 protein [Triiodothyronine co-treated with Chlorpyrifos] results in increased expression of GJA1 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in increased expression of GJA1 mRNA Triiodothyronine results in increased expression of GJA1 mRNA |
CTD |
PMID:15685554 PMID:34571837 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GPCPD1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GPD2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [BMS201038 results in increased expression of GPT protein] |
CTD |
PMID:34902352 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPX3 protein] |
CTD |
PMID:36868496 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
increases expression |
ISO |
Triiodothyronine results in increased expression of GRIK4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:36868496 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTA2 protein] |
CTD |
PMID:7532609 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTP1 protein] |
CTD |
PMID:7532609 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstp3 |
glutathione S-transferase pi 3 |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of GSTP3 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 1:201,355,682...201,358,216
Ensembl chr 1:201,355,682...201,358,330
|
|
G |
Gulp1 |
GULP PTB domain containing engulfment adaptor 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of GULP1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005
|
|
G |
H1f5 |
H1.5 linker histone, cluster member |
increases expression |
ISO |
Triiodothyronine results in increased expression of H1-5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Triiodothyronine analog results in increased phosphorylation of H2AX protein Triiodothyronine analog promotes the reaction [Cisplatin results in increased expression of H2AX protein] |
CTD |
PMID:22383522 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hba-a1 |
hemoglobin alpha, adult chain 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBA-A1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hbb |
hemoglobin subunit beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBB mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBG1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:158,271,871...158,273,426
Ensembl chr 1:158,271,873...158,273,425
|
|
G |
Hcn2 |
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HCN2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841
|
|
G |
Hdc |
histidine decarboxylase |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of HDC mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Heg1 |
heart development protein with EGF-like domains 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HEG1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Triiodothyronine results in increased expression of HIF1A mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Higd1a |
HIG1 hypoxia inducible domain family, member 1A |
increases expression |
EXP |
Triiodothyronine results in increased expression of HIGD1A mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:121,514,152...121,523,382
Ensembl chr 8:121,514,156...121,523,443
|
|
G |
Hira |
histone cell cycle regulator |
increases expression |
ISO |
Triiodothyronine results in increased expression of HIRA mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:82,024,469...82,133,212
Ensembl chr11:82,024,469...82,133,529
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HMGCS2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of HMOX1 protein] |
CTD |
PMID:36868496 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnph3 |
heterogeneous nuclear ribonucleoprotein H3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HNRNPH3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:25,616,400...25,625,814
Ensembl chr20:25,614,733...25,625,750
|
|
G |
Hr |
HR, lysine demethylase and nuclear receptor corepressor |
increases expression |
ISO |
Triiodothyronine results in increased expression of HR mRNA |
CTD |
PMID:25172293 PMID:26096596 |
|
NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313
|
|
G |
Hscb |
HscB mitochondrial iron-sulfur cluster co-chaperone |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of HSCB mRNA |
CTD |
PMID:23397585 |
|
NCBI chr12:45,821,527...45,831,902
Ensembl chr12:45,821,555...45,831,909
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:21726595 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hunk |
hormonally upregulated Neu-associated kinase |
increases expression |
ISO |
Triiodothyronine results in increased expression of HUNK mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of IDH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression increases secretion |
EXP |
Estradiol inhibits the reaction [Triiodothyronine results in increased expression of IGF1 mRNA]; Estradiol inhibits the reaction [Triiodothyronine results in increased secretion of IGF1 protein] |
CTD |
PMID:7684602 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of IGFBP2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Iglon5 |
IgLON family member 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of IGLON5 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:93,880,906...93,898,929
Ensembl chr 1:93,881,991...93,898,754
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Triiodothyronine results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein] Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL1B protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL1B protein] Triiodothyronine results in increased expression of IL1B mRNA |
CTD |
PMID:29796989 PMID:32223187 PMID:32816093 PMID:33476690 PMID:36868496 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Triiodothyronine results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein] Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL6 protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL6 mRNA] |
CTD |
PMID:29796989 PMID:32223187 PMID:36868496 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of INHA mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inhbb |
inhibin subunit beta B |
multiple interactions increases expression |
EXP |
FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA] |
CTD |
PMID:7531505 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA |
CTD |
PMID:26972250 PMID:33091441 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:27605626 PMID:33476690 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of INSIG1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of IRF1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [tamibarotene results in increased expression of ITGAM protein] |
CTD |
PMID:11201846 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itgb5 |
integrin subunit beta 5 |
increases expression decreases expression |
ISO |
Triiodothyronine results in increased expression of ITGB5 mRNA Triiodothyronine results in decreased expression of ITGB5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
increases expression |
ISO |
Triiodothyronine results in increased expression of ITPK1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 6:121,710,750...121,844,501
Ensembl chr 6:121,710,755...121,844,107
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ITPR1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Kantr |
KANTR integral membrane protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of KANTR mRNA |
CTD |
PMID:25172293 |
|
NCBI chr X:21,402,717...21,430,663
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of KCNA1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcna4 |
potassium voltage-gated channel subfamily A member 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of KCNA4 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:93,756,399...93,778,004
Ensembl chr 3:93,756,446...93,769,162
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein |
CTD |
PMID:27605626 |
|
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of KCTD12 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
Triiodothyronine results in increased expression of KIF1B mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Klf9 |
KLF transcription factor 9 |
decreases expression increases expression |
ISO |
Triiodothyronine results in decreased expression of KLF9 mRNA Triiodothyronine results in increased expression of KLF9 mRNA |
CTD |
PMID:15507505 PMID:23397585 PMID:26096596 PMID:35172007 |
|
NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Krt13 |
keratin 13 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of KRT13 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
decreases activity |
EXP |
Triiodothyronine results in decreased activity of KYAT1 protein |
CTD |
PMID:32663543 |
|
NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Amiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA]; desethylamiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA] Triiodothyronine inhibits the reaction [Amiodarone results in decreased expression of LDLR protein] |
CTD |
PMID:9071962 PMID:9712728 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lgi4 |
leucine-rich repeat LGI family, member 4 |
increases expression |
ISO |
Triiodothyronine results in increased expression of LGI4 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:86,294,539...86,305,909
Ensembl chr 1:86,295,074...86,304,874
|
|
G |
Lhx3 |
LIM homeobox 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LHX3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:9,026,432...9,035,122
Ensembl chr 3:9,027,425...9,034,480
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
Triiodothyronine results in increased expression of LIPE mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LMCD1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
|
|
G |
Lpin3 |
lipin 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of LPIN3 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
Triiodothyronine results in increased expression of LPL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [[Iodine deficiency co-treated with Propylthiouracil] results in decreased expression of LRP1 protein] |
CTD |
PMID:23517243 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Lss |
lanosterol synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of LSS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Ltb4r |
leukotriene B4 receptor |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of LTB4R mRNA |
CTD |
PMID:14761676 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Lyrm9 |
LYR motif containing 9 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LYRM9 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:63,725,718...63,739,772
Ensembl chr10:63,725,743...63,739,772
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases lipidation increases expression multiple interactions |
ISO |
Triiodothyronine results in increased lipidation of MAP1LC3B protein Triiodothyronine results in increased expression of MAP1LC3B mRNA bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO EXP |
Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK1 mRNA] Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12805413 PMID:16150908 PMID:28315333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO EXP |
Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK3 mRNA] Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12805413 PMID:16150908 PMID:28315333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of and results in increased phosphorylation of MAPT protein] |
CTD |
PMID:36868496 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mb |
myoglobin |
affects expression |
EXP |
Triiodothyronine affects the expression of MB mRNA |
CTD |
PMID:25098716 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mbp |
myelin basic protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of MBP protein alternative form |
CTD |
PMID:15345905 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ME1 mRNA |
CTD |
PMID:15953391 PMID:29357290 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Meioc |
meiosis specific with coiled-coil domain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of MEIOC mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:87,628,807...87,646,485
Ensembl chr10:87,628,875...87,646,752
|
|
G |
Mfsd2a |
MFSD2 lysolipid transporter A, lysophospholipid |
increases expression |
ISO |
Triiodothyronine results in increased expression of MFSD2A mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G |
Mier3 |
MIER family member 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of MIER3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:43,287,546...43,316,422
Ensembl chr 2:43,287,916...43,316,136
|
|
G |
Minpp1-ps1 |
multiple inositol-polyphosphate phosphatase 1, pseudogene 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of RGD1564801 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:74,017,248...74,019,633
Ensembl chr 1:230,354,438...230,379,730
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of MKI67 mRNA U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MKI67 mRNA] |
CTD |
PMID:28315333 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmd2 |
monocyte to macrophage differentiation-associated 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of MMD2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr12:11,962,733...12,009,776
Ensembl chr12:11,962,757...12,009,773
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
multiple interactions increases expression |
ISO |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr20:12,730,846...12,739,629
Ensembl chr20:12,730,836...12,739,628
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein] [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA |
CTD |
PMID:18031379 PMID:33091441 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased activity of MPO protein |
CTD |
PMID:7503757 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Msi1 |
musashi RNA-binding protein 1 |
multiple interactions |
ISO |
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of MSI1 mRNA |
CTD |
PMID:34289950 |
|
NCBI chr12:41,158,301...41,251,134
Ensembl chr12:41,158,599...41,191,076
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
Triiodothyronine results in decreased phosphorylation of MTOR protein |
CTD |
PMID:30209975 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions increases expression |
EXP |
S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of MYH6 mRNA] |
CTD |
PMID:11577024 PMID:15578571 PMID:15652358 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions decreases expression |
EXP |
Triiodothyronine inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA] Triiodothyronine results in decreased expression of MYH7 mRNA |
CTD |
PMID:11577024 PMID:15578571 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Naglt1 |
Na+ dependent glucose transporter 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NAGLT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr20:43,411,550...43,423,873
Ensembl chr20:43,394,843...43,423,873
|
|
G |
Ncapg2 |
non-SMC condensin II complex, subunit G2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NCAPG2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein] |
CTD |
PMID:22227104 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:29146198 PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein] |
CTD |
PMID:22227104 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein] |
CTD |
PMID:22227104 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Ndufa5 |
NADH:ubiquinone oxidoreductase subunit A5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NDUFA5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
|
|
G |
Nefl |
neurofilament light chain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NEFL mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NEFM mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of NFE2L2 protein] |
CTD |
PMID:33476690 PMID:36868496 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity multiple interactions |
EXP |
Triiodothyronine results in increased activity of NFKB1 protein Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of NFKB1 protein] |
CTD |
PMID:15019085 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA |
CTD |
PMID:33476690 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nnat |
neuronatin |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of NNAT mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Npnt |
nephronectin |
increases expression |
ISO |
Triiodothyronine results in increased expression of NPNT mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NR0B2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Triiodothyronine binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:21726595 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nrgn |
neurogranin |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of NRGN mRNA; Triiodothyronine results in increased expression of NRGN protein Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of and results in decreased phosphorylation of NRGN protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of NRGN mRNA] |
CTD |
PMID:15708448 PMID:29796989 |
|
NCBI chr 8:37,255,462...37,263,659
Ensembl chr 8:37,256,930...37,257,516
|
|
G |
Nrp1 |
neuropilin 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NRP1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
EXP |
Triiodothyronine results in increased expression of NSDHL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsmf |
NMDA receptor synaptonuclear signaling and neuronal migration factor |
increases expression |
EXP |
Triiodothyronine results in increased expression of NSMF mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:7,861,846...7,870,615
Ensembl chr 3:7,861,872...7,870,614
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression increases activity |
EXP |
Triiodothyronine results in increased expression of NT5E mRNA Triiodothyronine results in increased activity of NT5E protein |
CTD |
PMID:15543949 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nudt7 |
nudix hydrolase 7 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NUDT7 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081
|
|
G |
Nup214 |
nucleoporin 214 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of NUP214 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 3:15,255,111...15,340,568
Ensembl chr 3:15,255,119...15,340,568
|
|
G |
Ocln |
occludin |
increases expression |
EXP |
Triiodothyronine results in increased expression of OCLN mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Olr59 |
olfactory receptor 59 |
increases expression |
EXP |
Triiodothyronine results in increased expression of OLR59 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of OSGIN1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions affects binding |
EXP |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to P4HB protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Polychlorinated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to P4HB protein] |
CTD |
PMID:17928132 PMID:18515855 PMID:19374345 PMID:22201216 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Padi4 |
peptidyl arginine deiminase 4 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PADI4 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:153,041,351...153,074,412
Ensembl chr 5:153,041,352...153,074,362
|
|
G |
Parp4 |
poly (ADP-ribose) polymerase family, member 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PARP4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr15:30,690,503...30,792,868
Ensembl chr15:30,686,613...30,828,810
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
EXP ISO |
SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA] (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA] |
CTD |
PMID:21815645 PMID:23209300 PMID:30209975 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects binding increases expression multiple interactions |
ISO |
Triiodothyronine analog binds to PCNA protein; Triiodothyronine binds to PCNA protein Triiodothyronine results in increased expression of PCNA protein THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein] Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein] |
CTD |
PMID:20638743 PMID:22383522 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk1 |
proprotein convertase subtilisin/kexin type 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PCSK1 mRNA |
CTD |
PMID:15291740 |
|
NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PCSK2 mRNA |
CTD |
PMID:15585599 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions increases expression |
ISO EXP |
resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] |
CTD |
PMID:23209300 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp2 |
pyruvate dehydrogenase phosphatase catalytic subunit 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PDP2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074
|
|
G |
Peg10 |
paternally expressed 10 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PEG10 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Pex5 |
peroxisomal biogenesis factor 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PEX5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:157,270,671...157,296,432
Ensembl chr 4:157,270,672...157,296,431
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
Triiodothyronine results in increased expression of PFKP mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Phospho1 |
phosphoethanolamine/phosphocholine phosphatase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PHOSPHO1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:80,762,062...80,769,596
Ensembl chr10:80,760,792...80,770,342
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
increases expression |
ISO |
Triiodothyronine results in increased expression of PIK3CD mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
increases expression |
EXP |
Triiodothyronine results in increased expression of PLA2G6 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Pld5 |
phospholipase D family, member 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PLD5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr13:87,895,694...88,232,868
Ensembl chr13:87,896,369...88,232,868
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PLIN2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Plin3 |
perilipin 3 |
multiple interactions |
ISO |
[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein] |
CTD |
PMID:24262987 |
|
NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Plxnc1 |
plexin C1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PLXNC1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PMP22 mRNA |
CTD |
PMID:29901742 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
increases expression decreases phosphorylation |
ISO |
Triiodothyronine results in increased expression of PNPLA2 mRNA Triiodothyronine results in decreased phosphorylation of PNPLA2 protein |
CTD |
PMID:30209975 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Podxl |
podocalyxin-like |
increases expression |
EXP |
Triiodothyronine results in increased expression of PODXL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G |
Pold3 |
DNA polymerase delta 3, accessory subunit |
multiple interactions |
ISO |
Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein] |
CTD |
PMID:22383522 |
|
NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of POLG mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of POMT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of POU5F1 mRNA Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA] |
CTD |
PMID:34571837 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
[GW 7647 results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [pirinixic acid results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Triiodothyronine inhibits the reaction [Acetaminophen results in decreased expression of PPARA mRNA] |
CTD |
PMID:19631232 PMID:25048947 PMID:33476690 PMID:35662663 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Triiodothyronine binds to and results in increased activity of PPARG protein |
CTD |
PMID:25048947 PMID:33049310 PMID:33476690 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of PPARGC1A mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA] [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein |
CTD |
PMID:23209300 PMID:30209975 PMID:33091441 PMID:33476690 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prdm16 |
PR/SET domain 16 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of PRDM16 mRNA [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA |
CTD |
PMID:30209975 PMID:33091441 |
|
NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601
|
|
G |
Prelp |
proline and arginine rich end leucine rich repeat protein |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PRELP mRNA |
CTD |
PMID:25172293 |
|
NCBI chr13:45,368,407...45,391,480
Ensembl chr13:45,370,533...45,380,270
|
|
G |
Prickle2 |
prickle planar cell polarity protein 2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PRICKLE2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:124,869,655...125,214,862
Ensembl chr 4:124,869,552...125,214,824
|
|
G |
Prl |
prolactin |
decreases expression increases secretion multiple interactions |
EXP |
Triiodothyronine results in decreased expression of PRL mRNA; Triiodothyronine results in decreased expression of PRL protein Triiodothyronine results in increased secretion of PRL protein bisphenol A inhibits the reaction [Triiodothyronine results in increased secretion of PRL protein]; Chlorodiphenyl (54% Chlorine) promotes the reaction [Triiodothyronine results in increased secretion of PRL protein] |
CTD |
PMID:3734668 PMID:17615682 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prokr1 |
prokineticin receptor 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PROKR1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:120,022,301...120,033,367
Ensembl chr 4:120,021,747...120,033,379
|
|
G |
Psca |
prostate stem cell antigen |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA protein] Triiodothyronine results in increased expression of PSCA mRNA; Triiodothyronine results in increased expression of PSCA protein |
CTD |
PMID:14761676 |
|
NCBI chr 7:106,598,203...106,603,114
Ensembl chr 7:106,595,284...106,609,746
|
|
G |
Psg29 |
pregnancy-specific beta-1-glycoprotein 29 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of PSG7 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of PSG7 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSG7 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr 1:77,974,849...77,997,680
Ensembl chr 1:77,974,850...77,997,680
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rab23 |
RAB23, member RAS oncogene family |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of RAB23 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 9:35,943,522...35,967,367
Ensembl chr 9:35,944,085...35,966,927
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
increases expression |
ISO |
Triiodothyronine results in increased expression of RAB3B mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of RARB mRNA |
CTD |
PMID:15708448 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases activity |
EXP |
Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of RELA protein] |
CTD |
PMID:15019085 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retsat |
retinol saturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of RETSAT mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Rhov |
ras homolog family member V |
increases expression |
ISO |
Triiodothyronine results in increased expression of RHOV mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:106,260,774...106,270,009
Ensembl chr 3:106,260,776...106,269,479
|
|
G |
Rpa2 |
replication protein A2 |
increases phosphorylation |
ISO |
Triiodothyronine analog results in increased phosphorylation of RPA2 protein |
CTD |
PMID:22383522 |
|
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Triiodothyronine results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rxrb |
retinoid X receptor beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of RXRB mRNA |
CTD |
PMID:15708448 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
increases expression |
EXP |
Triiodothyronine results in increased expression of RXRG mRNA |
CTD |
PMID:15708448 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
multiple interactions |
EXP |
S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA] |
CTD |
PMID:15652358 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of SC5D mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of SCD1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpina6 |
serpin family A member 6 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SERPINA6 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 6:122,780,040...122,790,274
Ensembl chr 6:122,780,043...122,790,349
|
|
G |
Serpina7 |
serpin family A member 7 |
affects binding |
ISO |
Triiodothyronine binds to SERPINA7 protein |
CTD |
PMID:20804816 PMID:21517007 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SIGMAR1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression affects response to substance |
EXP |
SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] Triiodothyronine results in increased expression of SIRT1 mRNA SIRT1 protein affects the susceptibility to Triiodothyronine |
CTD |
PMID:23209300 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC10A2 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
multiple interactions decreases expression |
ISO |
resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 mRNA]; resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 protein] Triiodothyronine results in decreased expression of SLC15A1 mRNA; Triiodothyronine results in decreased expression of SLC15A1 protein |
CTD |
PMID:26394120 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
multiple interactions increases uptake |
ISO |
bisphenol A inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; bosutinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Dasatinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Desipramine inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Genistein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Imatinib Mesylate inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Meclofenamic Acid inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Phloretin inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Sulfobromophthalein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine] |
CTD |
PMID:28119167 |
|
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC16A3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of SLC16A6 mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC16A6 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC1A2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc25a25 |
solute carrier family 25 member 25 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC25A25 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC2A1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein |
CTD |
PMID:27605626 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
EXP |
[Triiodothyronine co-treated with Fructose] results in increased expression of SLC2A5 mRNA |
CTD |
PMID:17485832 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC38A2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc43a2 |
solute carrier family 43 member 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC43A2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:60,375,462...60,420,838
Ensembl chr10:60,376,559...60,418,244
|
|
G |
Slc51b |
SLC51 subunit beta |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of SLC51B mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC51B mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Sned1 |
sushi, nidogen and EGF-like domains 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SNED1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:93,774,087...93,834,003
Ensembl chr 9:93,774,119...93,830,694
|
|
G |
Snora28 |
small nucleolar RNA, H/ACA box 28 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of SNORA28 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:130,591,965...130,592,090
Ensembl chr 6:130,591,965...130,592,090
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
ISO |
Triiodothyronine inhibits the reaction [Paraquat results in decreased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA] Triiodothyronine results in decreased expression of SOD1 mRNA |
CTD |
PMID:16738222 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
multiple interactions |
ISO |
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in decreased expression of SOX10 mRNA |
CTD |
PMID:34289950 |
|
NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions decreases expression |
ISO |
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of SOX9 mRNA Triiodothyronine results in decreased expression of SOX9 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Spen |
spen family transcriptional repressor |
increases expression |
ISO |
Triiodothyronine results in increased expression of SPEN mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811
|
|
G |
Sptlc2 |
serine palmitoyltransferase, long chain base subunit 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SPTLC2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:106,948,682...107,031,532
Ensembl chr 6:106,950,949...107,031,542
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein] Triiodothyronine results in increased expression of SQSTM1 mRNA |
CTD |
PMID:24262987 PMID:30209975 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression decreases activity |
EXP ISO |
SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA] |
CTD |
PMID:23209300 PMID:33476690 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srsf3 |
serine and arginine rich splicing factor 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of SFRS3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of STAR mRNA; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA] |
CTD |
PMID:21726595 PMID:34571837 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stard8 |
StAR-related lipid transfer domain containing 8 |
increases expression |
ISO |
Triiodothyronine results in increased expression of STARD8 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr X:64,079,079...64,196,052
Ensembl chr X:64,124,574...64,196,052
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:16150908 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
increases expression |
ISO |
Triiodothyronine results in increased expression of STAT5A mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
increases expression |
EXP |
Triiodothyronine results in increased expression of STAT5B mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
|
|
G |
Stk19 |
serine/threonine kinase 19 |
increases expression |
ISO |
Triiodothyronine results in increased expression of STK19 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:3,995,590...4,005,117
Ensembl chr20:3,995,587...4,005,116
|
|
G |
Stra8 |
stimulated by retinoic acid 8 |
decreases expression multiple interactions |
ISO |
Triiodothyronine results in decreased expression of STRA8 mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation multiple interactions affects sulfation |
ISO |
SULT1A1 protein results in increased sulfation of Triiodothyronine Triiodothyronine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] SULT1A1 gene polymorphism affects the sulfation of Triiodothyronine |
CTD |
PMID:11739018 PMID:15531517 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SULT2A1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Sult4a1 |
sulfotransferase family 4A, member 1 |
increases metabolic processing |
ISO |
SULT4A1 protein results in increased metabolism of Triiodothyronine |
CTD |
PMID:12039030 |
|
NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085
|
|
G |
Sycp1 |
synaptonemal complex protein 1 |
decreases expression multiple interactions |
ISO |
Triiodothyronine results in decreased expression of SYCP1 mRNA [Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 2:190,296,688...190,456,687
Ensembl chr 2:190,296,954...190,456,737
|
|
G |
Taf5l1 |
TATA-box binding protein associated factor 5 like 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TAF5L mRNA |
CTD |
PMID:23397585 |
|
NCBI chr19:51,991,704...52,011,001
Ensembl chr19:51,991,708...52,011,295
|
|
G |
Tcim |
transcriptional and immune response regulator |
multiple interactions increases expression |
ISO |
SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of TCIM mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr16:67,595,762...67,597,055
Ensembl chr16:67,593,410...67,597,581
|
|
G |
Tex264 |
testis expressed 264 |
increases expression |
EXP |
Triiodothyronine results in increased expression of TEX264 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 8:107,295,806...107,322,858
Ensembl chr 8:107,295,806...107,323,232
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tfeb |
transcription factor EB |
increases expression |
ISO |
Triiodothyronine results in increased expression of TFEB mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein]; Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:18031379 PMID:33476690 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgoln2 |
trans-golgi network protein 2 |
decreases expression increases expression |
ISO |
Triiodothyronine results in decreased expression of TGOLN2 mRNA Triiodothyronine results in increased expression of TGOLN2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions affects binding increases expression increases activity decreases expression |
ISO EXP |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRA protein]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRA protein]; [THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRA protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRA protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein] 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; [Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of THRA mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of THRA mRNA; CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRA mRNA; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to THRA protein]; THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of THRA mRNA] Triiodothyronine results in decreased expression of THRA mRNA Triiodothyronine results in increased expression of THRA mRNA; Triiodothyronine results in increased expression of THRA protein |
CTD |
PMID:7684602 PMID:9664232 PMID:11806713 PMID:12109914 PMID:12414890 PMID:12588052 PMID:15680168 PMID:15708448 PMID:16021636 PMID:16023420 PMID:16738222 PMID:19672399 PMID:21396401 PMID:21726595 PMID:22015988 PMID:22086976 PMID:23112079 PMID:23402801 PMID:24076165 PMID:24262987 PMID:24819616 PMID:25646720 PMID:27993100 PMID:28167136 PMID:29146198 PMID:29688519 PMID:29796989 PMID:31566444 PMID:32223187 PMID:33049310 PMID:33095664 PMID:34571837 More...
|
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions increases expression decreases expression affects binding increases response to substance increases activity |
ISO EXP |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRB protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,3,4,7,8-pentachlorodibenzofuran inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,4,6-tribromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-trichlorophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-triiodophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRB protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; 4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 6-OH-BDE-47 inhibits the reaction [Triiodothyronine binds to THRB protein]; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Amiodarone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol A analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; cyhalothrin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; deoxynivalenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein alternative form]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRB protein]; methoxyacetic acid promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRB protein]; pentabromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; systhane inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; T-2 Toxin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrachlorodian analog inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Tretinoin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRB protein]; Triclosan inhibits the reaction [Triiodothyronine binds to THRB protein]; Triiodothyronine binds to and results in increased activity of THRB protein; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein]; Zearalenone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein] Triiodothyronine results in decreased expression of THRB mRNA THRB protein results in increased susceptibility to Triiodothyronine Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein] Triiodothyronine results in increased expression of THRB mRNA; Triiodothyronine results in increased expression of THRB protein [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRB mRNA; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB protein] |
CTD |
PMID:2211641 PMID:8137729 PMID:11577024 PMID:11806713 PMID:12109914 PMID:12414890 PMID:12538616 PMID:12588052 PMID:15103026 PMID:15598685 PMID:15680168 PMID:15708448 PMID:16021636 PMID:16738222 PMID:18486176 PMID:18584933 PMID:18795168 PMID:19457453 PMID:19672399 PMID:20638743 PMID:20737425 PMID:21396401 PMID:22015988 PMID:22227104 PMID:23112079 PMID:23402801 PMID:24262987 PMID:25646720 PMID:27410513 PMID:27420076 PMID:27993100 PMID:28167136 PMID:28531659 PMID:28973306 PMID:29146198 PMID:29409039 PMID:29688519 PMID:29763311 PMID:31077750 PMID:31476497 PMID:31566444 PMID:33049310 PMID:33095664 PMID:34571837 More...
|
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions increases expression |
EXP ISO |
Triiodothyronine inhibits the reaction [Amiodarone results in increased expression of THRSP mRNA] [Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of THRSP mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in increased expression of THRSP mRNA Triiodothyronine results in increased expression of THRSP mRNA |
CTD |
PMID:2721112 PMID:10357836 PMID:15953391 PMID:28478156 PMID:34571837 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tmem184b |
transmembrane protein 184B |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of TMEM184B mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 7:110,925,092...110,967,975
Ensembl chr 7:110,925,092...110,967,943
|
|
G |
Tmem44 |
transmembrane protein 44 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TMEM44 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:70,181,120...70,216,958
Ensembl chr11:70,181,345...70,216,958
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF mRNA; [Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF protein; Hexachlorocyclohexane inhibits the reaction [Triiodothyronine results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of TNF mRNA] THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein] |
CTD |
PMID:15019085 PMID:29796989 PMID:32223187 PMID:36868496 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 protein] Triiodothyronine results in increased expression of TNFRSF9 mRNA; Triiodothyronine results in increased expression of TNFRSF9 protein |
CTD |
PMID:14761676 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of TOMM20 protein Chloroquine promotes the reaction [Triiodothyronine results in increased expression of TOMM20 protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 protein] Triiodothyronine results in increased expression of TRAF1 mRNA; Triiodothyronine results in increased expression of TRAF1 protein |
CTD |
PMID:14761676 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Trim46 |
tripartite motif-containing 46 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TRIM46 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:174,641,494...174,654,237
Ensembl chr 2:174,641,496...174,654,141
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
decreases expression multiple interactions increases secretion |
ISO EXP |
Triiodothyronine results in decreased expression of TSHB mRNA [Triiodothyronine co-treated with 2,2',4,4'-tetrabromodiphenyl ether] results in decreased expression of TSHB mRNA alternative form TSHB protein results in increased secretion of Triiodothyronine |
CTD |
PMID:7827627 PMID:9092800 PMID:11288978 PMID:27420076 PMID:28167136 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ttbk1 |
tau tubulin kinase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TTBK1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:14,493,166...14,538,372
Ensembl chr 9:14,493,389...14,535,774
|
|
G |
Ttn |
titin |
multiple interactions affects expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine affects the expression of TTN mRNA]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA] |
CTD |
PMID:18096819 |
|
NCBI chr 3:61,652,432...61,924,912
Ensembl chr 3:61,652,439...61,924,741
|
|
G |
Ttr |
transthyretin |
affects binding |
ISO |
Triiodothyronine binds to TTR protein |
CTD |
PMID:20804816 PMID:21517007 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions increases expression |
ISO EXP |
(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] Triiodothyronine results in increased expression of UCP1 mRNA; Triiodothyronine results in increased expression of UCP1 protein [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 PMID:26972250 PMID:30209975 PMID:33091441 PMID:33476690 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [Bezafibrate results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [carboprostacyclin results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA] |
CTD |
PMID:12588052 PMID:25048947 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ugcg |
UDP-glucose ceramide glucosyltransferase |
increases activity |
EXP |
Triiodothyronine results in increased activity of UGCG protein |
CTD |
PMID:9101438 |
|
NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases expression multiple interactions |
EXP |
Triiodothyronine results in decreased expression of UGT1A1 mRNA Vitamin A inhibits the reaction [Triiodothyronine results in decreased expression of UGT1A1 mRNA] |
CTD |
PMID:11299074 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of UGT1A6 mRNA Vitamin A inhibits the reaction [Triiodothyronine results in increased expression of UGT1A6 mRNA] |
CTD |
PMID:11299074 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Utp20 |
UTP20 small subunit processome component |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UTP20 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 7:23,134,630...23,215,639
Ensembl chr 7:23,134,637...23,215,632
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of VDAC1 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wls |
Wnt ligand secretion mediator |
increases expression |
ISO |
Triiodothyronine results in increased expression of WLS mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:248,931,885...249,047,248
Ensembl chr 2:248,931,903...249,048,298
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of WNT4 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of WNT4 mRNA |
CTD |
PMID:34571837 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Zc3h7b |
zinc finger CCCH-type containing 7B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ZC3H7B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:113,262,142...113,310,399
Ensembl chr 7:113,262,165...113,310,399
|
|
G |
Zfp113 |
zinc finger protein 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ZNF3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr12:17,022,104...17,033,776
Ensembl chr12:17,022,279...17,033,709
|
|
G |
Zfp664 |
zinc finger protein 664 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ZNF664 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr12:31,767,792...31,796,038
Ensembl chr12:31,767,720...31,796,545
|
|
G |
Zmiz1 |
zinc finger, MIZ-type containing 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ZMIZ1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr16:1,027,083...1,232,616
Ensembl chr16:1,027,325...1,232,597
|
|
|
G |
Aadat |
aminoadipate aminotransferase |
affects activity multiple interactions |
EXP |
Thyroxine affects the activity of AADAT protein Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of AADAT protein] |
CTD |
PMID:32663543 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases abundance |
EXP |
ABCC2 results in decreased abundance of Thyroxine |
CTD |
PMID:19211616 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR affects the reaction [2,4,6-triphenyl-1-hexene results in increased abundance of Thyroxine] |
CTD |
PMID:18560529 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of AKT1 mRNA]; Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of and results in increased phosphorylation of AKT1 protein]; Thyroxine inhibits the reaction [Propylthiouracil results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:35101570 PMID:37295576 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Thyroxine binds to ALB protein 2,2',4,5'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to ALB protein]; Flame Retardants analog inhibits the reaction [Thyroxine binds to ALB protein] |
CTD |
PMID:20039755 PMID:21517007 PMID:29283575 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions |
EXP |
Thyroxine affects the reaction [Propylthiouracil affects the expression of AMH mRNA] |
CTD |
PMID:7819453 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Apod |
apolipoprotein D |
increases expression |
EXP |
Thyroxine results in increased expression of APOD mRNA; Thyroxine results in increased expression of APOD protein |
CTD |
PMID:31414343 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
App |
amyloid beta precursor protein |
decreases cleavage decreases expression |
ISO |
Thyroxine results in decreased cleavage of APP protein Thyroxine results in decreased expression of APP mRNA; Thyroxine results in decreased expression of APP protein |
CTD |
PMID:17199430 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions decreases expression |
ISO |
[nano-diamino-tetrac co-treated with Resveratrol] inhibits the reaction [Thyroxine results in decreased expression of BAD mRNA]; Resveratrol inhibits the reaction [Thyroxine results in decreased expression of BAD mRNA]; Thyroxine inhibits the reaction [Resveratrol results in increased expression of BAD mRNA] |
CTD |
PMID:31336132 PMID:31883986 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of BCL2 protein] |
CTD |
PMID:35101570 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cat |
catalase |
multiple interactions decreases activity decreases expression |
EXP |
[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; [Vitamin E co-treated with Curcumin] inhibits the reaction [Thyroxine results in decreased activity of CAT protein]; arotinolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT protein]; Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of CAT protein] Thyroxine results in decreased expression of CAT mRNA; Thyroxine results in decreased expression of CAT protein |
CTD |
PMID:2575990 PMID:18723006 PMID:19914224 PMID:34047416 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO |
Thyroxine results in increased expression of CCND1 mRNA [Resveratrol co-treated with nano-diamino-tetrac] inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA] |
CTD |
PMID:31336132 PMID:31883986 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd274 |
CD274 molecule |
increases expression multiple interactions |
ISO |
Thyroxine results in increased expression of CD274 mRNA; Thyroxine results in increased expression of CD274 protein; Thyroxine results in increased expression of PDL1 mRNA; Thyroxine results in increased expression of PDL1 protein [Resveratrol co-treated with nano-diamino-tetrac] inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CD274 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CD274 protein]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; NSC 74859 inhibits the reaction [Thyroxine results in increased expression of PDL1 protein]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of PDL1 protein] |
CTD |
PMID:29960019 PMID:31336132 PMID:31883986 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA |
CTD |
PMID:34323617 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Thyroxine results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Thyroxine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
EXP |
Thyroxine results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:10393316 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dcn |
decorin |
decreases expression |
ISO |
Thyroxine results in decreased expression of DCN mRNA |
CTD |
PMID:23935926 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
affects abundance increases metabolic processing multiple interactions affects metabolic processing increases expression |
ISO EXP |
DIO1 gene SNP affects the abundance of Thyroxine DIO1 protein results in increased metabolism of Thyroxine [DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine] DIO1 protein affects the metabolism of Thyroxine Thyroxine results in increased expression of DIO1 mRNA 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine results in increased expression of DIO1 mRNA] |
CTD |
PMID:15254343 PMID:17105838 PMID:21565810 PMID:27420076 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions affects metabolic processing increases metabolic processing decreases activity decreases expression |
ISO EXP |
2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [Aurothioglucose results in decreased activity of DIO2 protein] which affects the metabolism of Thyroxine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; [xanthohumol results in decreased activity of DIO2 protein] which affects the metabolism of Thyroxine; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; lactacystin inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; Thyroxine results in decreased expression of and results in decreased activity of DIO2 protein DIO2 protein mutant form affects the metabolism of Thyroxine Thyroxine results in decreased expression of DIO2 mRNA 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine results in decreased expression of DIO2 mRNA] |
CTD |
PMID:11108274 PMID:11425850 PMID:16728495 PMID:17615150 PMID:25962824 PMID:26004626 PMID:27420076 More...
|
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases activity multiple interactions |
EXP |
Thyroxine results in increased activity of DIO3 protein Hydrogen Peroxide promotes the reaction [Thyroxine results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
increases expression |
ISO |
Thyroxine results in increased expression of DMP1 mRNA |
CTD |
PMID:23935926 |
|
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
|
|
G |
Duox1 |
dual oxidase 1 |
decreases expression |
ISO |
Thyroxine results in decreased expression of DUOX1 protein |
CTD |
PMID:17332529 |
|
NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563
|
|
G |
Duox2 |
dual oxidase 2 |
decreases expression |
ISO |
Thyroxine results in decreased expression of DUOX2 protein |
CTD |
PMID:17332529 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
Thyroxine results in increased expression of FGF1 mRNA |
CTD |
PMID:23935926 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Thyroxine results in increased expression of FGF2 mRNA |
CTD |
PMID:23935926 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
EXP |
Thyroxine results in decreased expression of FLT1 mRNA |
CTD |
PMID:25499719 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression multiple interactions |
EXP |
Thyroxine results in increased expression of GAP43 mRNA Thyroxine inhibits the reaction [Ethanol results in decreased expression of GAP43 mRNA] |
CTD |
PMID:15940294 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gh1 |
growth hormone 1 |
decreases abundance multiple interactions |
ISO |
GH1 protein results in decreased abundance of Thyroxine [2,2',4,4'-tetrabromodiphenyl ether co-treated with Thyroxine] results in increased expression of GH mRNA |
CTD |
PMID:17311540 PMID:17324600 PMID:27420076 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
multiple interactions |
EXP |
Ipodate inhibits the reaction [Thyroxine results in increased activity of GPD2 protein]; Propylthiouracil inhibits the reaction [Thyroxine results in increased activity of GPD2 protein] |
CTD |
PMID:6723573 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of GPT protein] |
CTD |
PMID:34047416 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression increases expression decreases activity increases activity |
EXP |
[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in increased expression of GPX1 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of GPX1 mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of GPX1 mRNA] Thyroxine results in decreased activity of GPX1 protein Thyroxine results in increased activity of GPX1 protein |
CTD |
PMID:19914224 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases expression decreases activity |
EXP |
[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA] Thyroxine results in decreased expression of GSR mRNA; Thyroxine results in decreased expression of GSR protein Thyroxine results in decreased activity of GSR protein |
CTD |
PMID:19914224 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
EXP |
[Propylthiouracil results in increased abundance of Thyroxine] which results in increased expression of HES1 mRNA |
CTD |
PMID:15862623 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
multiple interactions |
EXP |
[Propylthiouracil results in increased abundance of Thyroxine] which results in increased expression of HES5 mRNA |
CTD |
PMID:15862623 |
|
NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
|
|
G |
Hr |
HR, lysine demethylase and nuclear receptor corepressor |
increases expression |
EXP |
Thyroxine results in increased expression of HR mRNA |
CTD |
PMID:29901742 |
|
NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
EXP |
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of HRAS protein] |
CTD |
PMID:35101570 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
increases expression |
ISO |
Thyroxine results in increased expression of HTRA1 mRNA |
CTD |
PMID:23935926 |
|
NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Ifng |
interferon gamma |
increases expression |
EXP |
Thyroxine results in increased expression of IFNG mRNA; Thyroxine results in increased expression of IFNG protein |
CTD |
PMID:24534949 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
Thyroxine results in increased expression of IGF1 mRNA |
CTD |
PMID:23935926 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions increases expression |
EXP |
Vitamin E inhibits the reaction [Thyroxine results in increased expression of IGF1R protein] |
CTD |
PMID:17447016 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
Thyroxine results in increased expression of IL10 mRNA |
CTD |
PMID:24534949 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
NSC 74859 inhibits the reaction [Thyroxine results in increased expression of IL1B mRNA] |
CTD |
PMID:31336132 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of IL6 protein] |
CTD |
PMID:34047416 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Itgav |
integrin subunit alpha V |
multiple interactions |
EXP |
[Methamphetamine co-treated with Thyroxine] results in increased expression of ITGAV protein |
CTD |
PMID:35301009 |
|
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression decreases expression |
EXP |
Thyroxine results in increased expression of KDR mRNA; Thyroxine results in increased expression of KDR protein Thyroxine results in decreased expression of KDR mRNA |
CTD |
PMID:25298361 PMID:25499719 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
multiple interactions affects activity |
EXP |
Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of KYAT1 protein] Thyroxine affects the activity of KYAT1 protein |
CTD |
PMID:32663543 |
|
NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions affects localization increases phosphorylation |
ISO EXP |
NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of MAPK1 protein] tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK1 protein] |
CTD |
PMID:17984113 PMID:31336132 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions affects localization increases phosphorylation |
ISO EXP |
NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of MAPK3 protein] tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK3 protein] |
CTD |
PMID:17984113 PMID:31336132 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
increases expression |
EXP |
Thyroxine results in increased expression of MCM7 protein |
CTD |
PMID:25298361 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression affects expression |
EXP |
Thyroxine results in increased expression of MIF protein Thyroxine affects the expression of MIF mRNA |
CTD |
PMID:24534949 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression |
EXP |
Thyroxine results in increased expression of MMP2 mRNA |
CTD |
PMID:24534949 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
Thyroxine results in increased expression of MMP9 mRNA |
CTD |
PMID:23935926 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Thyroxine promotes the reaction [THRA protein binds to NCOA2 protein]; Thyroxine promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein] |
CTD |
PMID:22227104 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein] |
CTD |
PMID:22227104 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Nos1 |
nitric oxide synthase 1 |
increases expression |
EXP |
Thyroxine results in increased expression of NOS1 protein |
CTD |
PMID:31463706 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP |
Thyroxine results in increased expression of NOS2 protein |
CTD |
PMID:24534949 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
EXP |
Thyroxine results in increased expression of NOS3 mRNA; Thyroxine results in increased expression of NOS3 protein |
CTD |
PMID:31463706 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Thyroxine results in increased activity of NR1I2 protein [Thyroxine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects metabolic processing |
ISO |
NR1I3 protein affects the metabolism of Thyroxine |
CTD |
PMID:15004031 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases expression |
EXP |
Thyroxine inhibits the reaction [Ethanol results in decreased expression of NR3C1 mRNA] Thyroxine results in increased expression of NR3C1 mRNA |
CTD |
PMID:15940294 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
EXP |
Ipodate inhibits the reaction [Thyroxine results in increased activity of ODC1 protein]; Propylthiouracil inhibits the reaction [Thyroxine results in increased activity of ODC1 protein] |
CTD |
PMID:6723573 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
decreases expression |
EXP |
Thyroxine results in decreased expression of PCSK2 mRNA |
CTD |
PMID:15585599 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pgf |
placental growth factor |
increases expression |
EXP |
Thyroxine results in increased expression of PGF mRNA |
CTD |
PMID:25499719 |
|
NCBI chr 6:104,816,102...104,826,685
Ensembl chr 6:104,816,104...104,826,685
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
increases expression |
ISO |
Thyroxine results in increased expression of PHEX mRNA |
CTD |
PMID:23935926 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases expression |
ISO EXP |
Thyroxine results in increased expression of PMP22 mRNA |
CTD |
PMID:29901742 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
Thyroxine results in increased expression of POR mRNA |
CTD |
PMID:23935926 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Thyroxine inhibits the reaction [Triclosan results in decreased expression of PPARG protein] |
CTD |
PMID:28973666 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
EXP ISO |
Thyroxine inhibits the reaction [resveratrol affects the localization of PTGS2 protein] [Resveratrol co-treated with nano-diamino-tetrac] promotes the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; nano-diamino-tetrac promotes the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; Thyroxine inhibits the reaction [Resveratrol affects the localization of PTGS2 protein]; Thyroxine inhibits the reaction [Resveratrol results in increased expression of PTGS2 mRNA] Thyroxine results in increased expression of PTGS2 protein |
CTD |
PMID:17984113 PMID:25298361 PMID:31336132 PMID:31883986 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
Thyroxine binds to RXRA protein |
CTD |
PMID:31566444 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Sdha |
succinate dehydrogenase complex flavoprotein subunit A |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein |
CTD |
PMID:34323617 |
|
NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535
|
|
G |
Sema7a |
semaphorin 7A (John Milton Hagen blood group) |
increases expression |
EXP |
Thyroxine results in increased expression of SEMA7A mRNA |
CTD |
PMID:29901742 |
|
NCBI chr 8:58,348,448...58,370,536
Ensembl chr 8:58,348,448...58,370,536
|
|
G |
Serpina7 |
serpin family A member 7 |
multiple interactions affects binding |
ISO |
3,5-dichlorobiphenyl metabolite inhibits the reaction [Thyroxine binds to SERPINA7 protein]; bisphenol A inhibits the reaction [Thyroxine binds to SERPINA7 protein]; tetrabromobisphenol A inhibits the reaction [Thyroxine binds to SERPINA7 protein]; tetrachlorodian inhibits the reaction [Thyroxine binds to SERPINA7 protein] |
CTD |
PMID:16478101 PMID:20804816 PMID:21517007 PMID:27528273 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Shh |
sonic hedgehog signaling molecule |
increases expression |
EXP |
Thyroxine results in increased expression of SHH mRNA |
CTD |
PMID:29901742 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression |
ISO |
Thyroxine results in increased expression of SIRT1 protein |
CTD |
PMID:18204789 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Thyroxine inhibits the reaction [Triclosan results in decreased expression of SLC2A4 protein] |
CTD |
PMID:28973666 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc30a10 |
solute carrier family 30, member 10 |
decreases chemical synthesis |
ISO |
SLC30A10 gene mutant form results in decreased chemical synthesis of Thyroxine |
CTD |
PMID:28860195 |
|
NCBI chr13:96,998,143...97,048,076
Ensembl chr13:96,998,143...97,009,103
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
decreases expression |
ISO |
Thyroxine results in decreased expression of SLC5A5 protein |
CTD |
PMID:17332529 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression decreases activity increases activity increases expression |
EXP |
[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; [Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; [Curcumin co-treated with Vitamin E] promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]; Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; Curcumin inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; Curcumin promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]; Thyroxine inhibits the reaction [Zinc deficiency results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in increased expression of SOD1 protein]; Vitamin E promotes the reaction [Thyroxine results in decreased activity of SOD1 protein] Thyroxine results in decreased expression of SOD1 mRNA; Thyroxine results in decreased expression of SOD1 protein |
CTD |
PMID:2575990 PMID:10381190 PMID:17447016 PMID:19914224 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression decreases expression decreases activity |
EXP |
[Vitamin E co-treated with Curcumin] inhibits the reaction [Thyroxine results in decreased expression of SOD2 mRNA]; Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased activity of SOD2 protein]; Curcumin promotes the reaction [Thyroxine results in increased expression of SOD2 protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD2 mRNA]; Vitamin E promotes the reaction [Thyroxine results in increased expression of SOD2 protein] |
CTD |
PMID:2575990 PMID:19914224 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
ISO |
NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31336132 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
affects sulfation increases sulfation multiple interactions |
ISO |
SULT1A1 gene polymorphism affects the sulfation of Thyroxine SULT1A1 protein results in increased sulfation of Thyroxine Thyroxine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] |
CTD |
PMID:11739018 PMID:15531517 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult4a1 |
sulfotransferase family 4A, member 1 |
increases metabolic processing |
ISO |
SULT4A1 protein results in increased metabolism of Thyroxine |
CTD |
PMID:12039030 |
|
NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085
|
|
G |
Syn1 |
synapsin I |
multiple interactions |
ISO |
Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYN1 mRNA] |
CTD |
PMID:27413119 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYP mRNA] |
CTD |
PMID:27413119 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
NSC 74859 inhibits the reaction [Thyroxine results in increased expression of TGFB1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of TGFB1 mRNA] |
CTD |
PMID:31336132 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thra |
thyroid hormone receptor alpha |
affects binding multiple interactions increases expression |
ISO EXP |
Thyroxine binds to THRA protein [bisphenol A co-treated with Estradiol co-treated with Thyroxine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Thyroxine] results in increased expression of THRA mRNA Thyroxine results in increased expression of THRA mRNA Thyroxine promotes the reaction [THRA protein binds to NCOA2 protein] |
CTD |
PMID:23112079 PMID:23402801 PMID:27993100 PMID:31566444 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions affects binding increases activity increases expression decreases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Thyroxine promotes the reaction [THRB protein binds to NCOA2 protein] Thyroxine binds to THRB protein Thyroxine results in increased activity of THRB protein [bisphenol A co-treated with Estradiol co-treated with Thyroxine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Thyroxine] results in increased expression of THRB mRNA Thyroxine results in increased expression of THRB mRNA Thyroxine results in decreased expression of THRB mRNA |
CTD |
PMID:18584933 PMID:19457453 PMID:22227104 PMID:23112079 PMID:23402801 PMID:27420076 PMID:27993100 PMID:29409039 PMID:31077750 PMID:31566444 More...
|
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions decreases expression |
ISO EXP |
Thyroxine results in increased expression of TNF mRNA Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of TNF protein] Thyroxine results in decreased expression of TNF mRNA |
CTD |
PMID:23935926 PMID:24534949 PMID:34047416 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects localization multiple interactions |
EXP |
Thyroxine affects the localization of TP53 protein modified form tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of TP53 protein modified form] |
CTD |
PMID:17984113 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpo |
thyroid peroxidase |
multiple interactions |
EXP |
[Propylthiouracil results in decreased activity of TPO protein] which results in decreased chemical synthesis of and results in decreased abundance of Thyroxine |
CTD |
PMID:28973696 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Trpm7 |
transient receptor potential cation channel, subfamily M, member 7 |
decreases abundance |
ISO |
TRPM7 gene mutant form results in decreased abundance of Thyroxine |
CTD |
PMID:30770447 |
|
NCBI chr 3:114,046,258...114,134,799
Ensembl chr 3:114,046,258...114,135,190
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions decreases expression |
EXP ISO |
Clofibrate inhibits the reaction [Thyroxine results in decreased expression of TSHB protein]; Thyroxine inhibits the reaction [lead acetate results in decreased expression of TSHB protein]; Thyroxine inhibits the reaction [pexacerfont results in increased expression of TSHB protein]; Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of TSHB protein] Thyroxine results in decreased expression of TSHB mRNA |
CTD |
PMID:18219302 PMID:21871911 PMID:27420076 PMID:33340518 PMID:34047416 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
decreases activity |
ISO |
Thyroxine results in decreased activity of TSHR protein |
CTD |
PMID:17332529 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Ttr |
transthyretin |
multiple interactions affects binding |
ISO EXP |
2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',3,3',4,4',5-heptachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether analog inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,5'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to TTR protein]; 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 3,5-dichlorobiphenyl metabolite inhibits the reaction [Thyroxine binds to TTR protein]; 4-nonylphenol inhibits the reaction [Thyroxine binds to TTR protein]; bisphenol A inhibits the reaction [Thyroxine binds to TTR protein]; Diethylstilbestrol inhibits the reaction [Thyroxine binds to TTR protein]; Flame Retardants analog inhibits the reaction [Thyroxine binds to TTR protein]; Flame Retardants inhibits the reaction [Thyroxine binds to TTR protein]; Halogenated Diphenyl Ethers analog inhibits the reaction [Thyroxine binds to TTR protein]; PCB 180 inhibits the reaction [Thyroxine binds to TTR protein]; pentabromophenol inhibits the reaction [Thyroxine binds to TTR protein]; Pentachlorophenol inhibits the reaction [Thyroxine binds to TTR protein]; perfluoro-n-heptanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluoro-n-nonanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorobutanesulfonic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorobutyric acid affects the reaction [Thyroxine binds to TTR protein]; perfluorodecanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorododecanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorohexanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctane sulfonic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctane sulfonic acid inhibits the reaction [Thyroxine binds to TTR protein]; perfluorooctanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctanoic acid inhibits the reaction [Thyroxine binds to TTR protein]; perfluoroundecanoic acid affects the reaction [Thyroxine binds to TTR protein]; Polychlorinated Biphenyls analog inhibits the reaction [Thyroxine binds to TTR protein]; T-2 Toxin inhibits the reaction [Thyroxine binds to TTR protein]; tetrabromobisphenol A inhibits the reaction [Thyroxine binds to TTR protein]; tetrachlorodian inhibits the reaction [Thyroxine binds to TTR protein]; Thyroxine inhibits the reaction [1-anilino-8-naphthalenesulfonate binds to TTR protein]; Wastewater inhibits the reaction [Thyroxine binds to TTR protein] 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to TTR protein] |
CTD |
PMID:10631123 PMID:10869457 PMID:16478101 PMID:16601080 PMID:18161906 PMID:20039755 PMID:20804816 PMID:21357386 PMID:21517007 PMID:23584369 PMID:27528273 PMID:29283575 PMID:31077750 PMID:33095664 More...
|
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
Thyroxine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA] |
CTD |
PMID:12588052 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
EXP |
Thyroxine results in increased expression of UGT1A1 mRNA |
CTD |
PMID:17884940 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a3 |
UDP glycosyltransferase 1 family, polypeptide A3 |
increases expression |
EXP |
Thyroxine results in increased expression of UGT1A5 mRNA |
CTD |
PMID:17884940 |
|
NCBI chr 9:88,780,328...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a7c |
UDP glucuronosyltransferase 1 family, polypeptide A7C |
increases expression |
EXP |
Thyroxine results in increased expression of UGT1A7 mRNA |
CTD |
PMID:17884940 |
|
NCBI chr 9:88,739,577...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
EXP |
[Clofibrate co-treated with Thyroxine] results in increased activity of UGT1A9 protein |
CTD |
PMID:18219302 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions affects expression increases expression |
EXP |
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of VEGFA protein] Thyroxine affects the expression of VEGFA protein Thyroxine results in increased expression of VEGFA mRNA |
CTD |
PMID:25298361 PMID:25499719 PMID:35101570 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|